Boc-L-beta-HThr(Bzl)-OH

Boc-L-beta-HThr(Bzl)-OH is a protected, stereodefined amino acid building block featuring an N-terminal Boc protecting group and a side-chain benzyl (Bzl) protection on the hydroxyl-bearing threonine-related residue. This reagent is commonly used in peptide synthesis workflows where orthogonal protection and controlled reactivity are required to preserve side-chain functionality during coupling and deprotection steps. The presence of the Boc group supports acid-mediated N-terminal activation strategies, while the benzyl-protected hydroxyl helps maintain chemoselectivity for subsequent peptide assembly and downstream functionalization.

1. Solid-Phase Peptide Synthesis

Boc-L-beta-HThr(Bzl)-OH is frequently selected by peptide synthesis groups performing solid-phase peptide synthesis to incorporate a hydroxyl-bearing residue with side-chain protection that survives standard coupling conditions. The Boc-protected amino terminus supports routine activation and coupling into growing peptide chains, while the benzyl-protected side-chain hydroxyl minimizes undesired side reactions such as premature O-alkylation or hydrogen-bond-driven aggregation during synthesis. This makes the building block particularly useful for preparing peptides where later stages require controlled unveiling of the side-chain hydroxyl for further derivatization, including phosphorylation-like mimicry or conjugation strategies that depend on selective deprotection.

2. Protected Residue Incorporation

Boc-L-beta-HThr(Bzl)-OH is used in custom peptide manufacturing and research peptide library construction when a protected beta-hydroxy threonine motif is required with stable side-chain masking. Chemists rely on this form to maintain orthogonality between the N-terminal Boc group and the benzyl-protected hydroxyl, enabling stepwise deprotection and selective downstream transformations after peptide assembly. In practice, the reagent supports the preparation of peptides that need a protected hydroxyl functionality during iterative couplings, while still allowing the residue to be carried through purification and characterization as part of longer sequences.

3. Pharmaceutical Intermediate Peptide Segments

Boc-L-beta-HThr(Bzl)-OH is also applied in the development of protected peptide intermediates used for medicinal chemistry and peptide drug discovery programs. Teams preparing segment condensations or advanced intermediates use this building block to ensure the hydroxyl-bearing side chain remains protected throughout fragment assembly, protecting-group-compatible purification, and intermediate handling. The Boc/Bzl protection pattern supports downstream conversion of the assembled peptide segment into further derivatives, including analog generation where the hydroxyl group is a key handle for structure-activity relationship studies or for installing additional chemical functionality after the peptide segment is secured.

4. Orthogonally Protected Hydroxyl Handling

Boc-L-beta-HThr(Bzl)-OH is valued in chemical biology and biomolecular probe development workflows that require precise control over hydroxyl availability on a peptide scaffold. By keeping the side-chain hydroxyl benzyl-protected during synthesis, researchers can avoid side reactions that would otherwise complicate conjugation steps or introduce heterogeneity. After peptide assembly, the protected hydroxyl residue can be leveraged as a defined chemical handle for subsequent derivatization steps that depend on clean, site-specific functional group exposure, supporting reproducible probe or conjugate construction from a well-defined amino acid sequence.

1. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

2. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

3. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

4. Cationic cell-penetrating peptides are potent furin inhibitors

5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy